Key Metrics
12.97
Heat Index-
Impact LevelMedium
-
Scope LevelGlobal
-
Last Update2026-01-12
Key Impacts
Positive Impacts (6)
Rongchang Biopharma (688331.SH)
AbbVie Inc. (ABBV)
Chinese Biotech Equities
Bispecific Antibody Developers
Royalty & IP-Backed Financing Funds
China CRO Sector
Total impacts: 6 |
Positive: 6 |
Negative: 0
Event Overview
A pharmaceutical licensing agreement grants development, manufacturing, and commercialization rights for a novel bispecific antibody. The deal includes significant upfront payments, milestone payments, and royalties, reflecting the high value and potential of biopharmaceutical innovations in global markets.
Collect Records
荣昌生物与艾伯维集团签署独家授权许可协议
2026-01-12 20:51
荣昌生物与艾伯维集团签署了一份独家授权许可协议，根据协议，艾伯维将获得荣昌生物研发的新型双特异性抗体药物RC148在大中华区以外地区的开发、生产和商业化权利。协议生效后，荣昌生物将收到6.5亿美元首付款，并有资格获得最高达49.5亿美元的里程碑付款及净销售额的两位数分级特许权使用费。里程碑付款需满足一定条件，最终金额存在不确定性。该交易已获公司董事会批准，无需股东会审议。
Total records: 1